Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III confirmatory study of KP-001 in symptomatic refractory vascular malformations and Klippel-Trenaunay syndrome
jRCT2041230064Phase 3Completed
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of KP001 in venous malformation (VM), lymphangioma and Klippel-Trenaunay syndrome (KTS), sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoint: Target lesion response based on MRI. Started Aug 2023; status: completed.
02
Drugs
KP001
03
Conditions
venous malformation (VM)lymphangiomaKlippel-Trenaunay syndrome (KTS)
Beyond the preview
Go deeper on jRCT2041230064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230064.